Article Search
검색
검색 팝업 닫기

Metrics

Help

  • 1. Aims and Scope

    Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE

  • 2. Editorial Board

    Editor-in-Chief + MORE

    Editor-in-Chief
    Yong Chan Lee Professor of Medicine
    Director, Gastrointestinal Research Laboratory
    Veterans Affairs Medical Center, Univ. California San Francisco
    San Francisco, USA

    Deputy Editor

    Deputy Editor
    Jong Pil Im Seoul National University College of Medicine, Seoul, Korea
    Robert S. Bresalier University of Texas M. D. Anderson Cancer Center, Houston, USA
    Steven H. Itzkowitz Mount Sinai Medical Center, NY, USA
  • 3. Editorial Office
  • 4. Articles
  • 5. Instructions for Authors
  • 6. File Download (PDF version)
  • 7. Ethical Standards
  • 8. Peer Review

    All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
    The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.

    The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.

Search

Search

Year

to

Article Type

ahead

Split Viewer

Online first

Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease

Shun-Wen Hsiao1,2 , Hsu-Heng Yen1,3,4,5 , and Yang-Yuan Chen1,2,6

1Division of Gastroenterology, Changhua Christian Hospital, 2Division of Gastroenterology, Yuanlin Christian Hospital, 3General Education Center, Chienkuo Technology University, Changhua, 4Department of Electrical Engineering, Chung Yuan Christian University, Taoyuan, 5Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, and 6Department of Hospitality Management, MingDao University, Changhua, Taiwan

Correspondence to:Hsu-Heng Yen
ORCID https://orcid.org/0000-0001-5936-7112
E-mail 91646@cch.org.tw, blaneyen@gmail.com

Part of the work was presented in the AOCC 2020 which was held in Korea from December 16 to 18, 2020.

Received: October 16, 2021; Revised: November 20, 2021; Accepted: December 7, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gut Liver

Published online June 7, 2022

Copyright © Gut and Liver.

Abstract

The association between inflammatory bowel disease and colorectal cancer is well known. Although the overall incidence of inflammatory bowel disease has declined recently, patients with this disease still have a 1.7-fold increased risk of colorectal cancer. The risk factors for developing colorectal cancer include extensive colitis, young age at diagnosis, disease duration, primary sclerosing cholangitis, chronic colonic mucosal inflammation, dysplasia lesion, and post-inflammatory polyps. In patients with inflammatory bowel disease, control of chronic inflammation and surveillance colonoscopies are important for the prevention of colorectal cancer. The 2017 guidelines from the European Crohn’s and Colitis Organisation suggest that colonoscopies to screen for colorectal cancer should be performed when inflammatory bowel disease symptoms have lasted for 8 years. Current evidence supports the use of chemoprevention therapy with mesalamine to reduce the risk of colorectal cancer in patients with ulcerative colitis. Other compounds, including thiopurine, folic acid, statin, and tumor necrosis factor-α inhibitor, are controversial. Large surveillance cohort studies with longer follow-up duration are needed to evaluate the impact of drugs on colorectal cancer risks.

Keywords: Inflammatory bowel disease, Crohn disease, Ulcerative colitis


Article

ahead

Gut and Liver

Published online June 7, 2022

Copyright © Gut and Liver.

Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease

Shun-Wen Hsiao1,2 , Hsu-Heng Yen1,3,4,5 , and Yang-Yuan Chen1,2,6

1Division of Gastroenterology, Changhua Christian Hospital, 2Division of Gastroenterology, Yuanlin Christian Hospital, 3General Education Center, Chienkuo Technology University, Changhua, 4Department of Electrical Engineering, Chung Yuan Christian University, Taoyuan, 5Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, and 6Department of Hospitality Management, MingDao University, Changhua, Taiwan

Correspondence to:Hsu-Heng Yen
ORCID https://orcid.org/0000-0001-5936-7112
E-mail 91646@cch.org.tw, blaneyen@gmail.com

Part of the work was presented in the AOCC 2020 which was held in Korea from December 16 to 18, 2020.

Received: October 16, 2021; Revised: November 20, 2021; Accepted: December 7, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The association between inflammatory bowel disease and colorectal cancer is well known. Although the overall incidence of inflammatory bowel disease has declined recently, patients with this disease still have a 1.7-fold increased risk of colorectal cancer. The risk factors for developing colorectal cancer include extensive colitis, young age at diagnosis, disease duration, primary sclerosing cholangitis, chronic colonic mucosal inflammation, dysplasia lesion, and post-inflammatory polyps. In patients with inflammatory bowel disease, control of chronic inflammation and surveillance colonoscopies are important for the prevention of colorectal cancer. The 2017 guidelines from the European Crohn’s and Colitis Organisation suggest that colonoscopies to screen for colorectal cancer should be performed when inflammatory bowel disease symptoms have lasted for 8 years. Current evidence supports the use of chemoprevention therapy with mesalamine to reduce the risk of colorectal cancer in patients with ulcerative colitis. Other compounds, including thiopurine, folic acid, statin, and tumor necrosis factor-α inhibitor, are controversial. Large surveillance cohort studies with longer follow-up duration are needed to evaluate the impact of drugs on colorectal cancer risks.

Keywords: Inflammatory bowel disease, Crohn disease, Ulcerative colitis

Gut and Liver

Vol.16 No.3
May, 2022

pISSN 1976-2283
eISSN 2005-1212

qrcode
qrcode

Share this article on :

  • line

Popular Keywords

Gut and LiverQR code Download
qr-code

Editorial Office